WWM
ASND icon

Whalen Wealth Management’s Ascendis Pharma A/S ASND Stock Holding History

Whalen Wealth Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,867
Closed -$427K – 198
2026
Q1 		$427K Buy
+1,867
New +$419K 0.23% 112
2025
Q4 		– Sell
-4,620
Closed -$919K – 192
2025
Q3 		$919K Buy
+4,620
New +$862K 0.54% 44

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Whalen Wealth Management's ASND Position: Q2 2026 in Review

Whalen Wealth Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 1,867 shares — an estimated $427K sold.

Whalen Wealth Management first reported a position in ASND in Q3 2025 and held it in 2 quarters. The position peaked at $919K in Q3 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Whalen Wealth Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Whalen Wealth Management sold 1,867 Ascendis Pharma A/S shares in Q2 2026, an estimated $427K.
  • Whalen Wealth Management first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 2 quarters.
  • Whalen Wealth Management's Ascendis Pharma A/S position peaked at $919K in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Whalen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.